This experiment investigates the molecular mechanisms by which lifestyle interventions—physical exercise, cognitive engagement, diet, and social interaction—modify AD trajectory. Epidemiological evidence suggests these factors reduce AD risk, but the mechanisms are poorly understood.
AD Gap #19: Can lifestyle interventions modify disease trajectory?
What are the molecular mediators of exercise, diet, and cognitive reserve benefits, and can these be pharmacologically mimicked?
Lifestyle interventions work through convergent biological pathways: reduced neuroinflammation, enhanced neurogenesis, improved cerebral blood flow, and strengthened synaptic resilience. Understanding these mechanisms will enable pharmacological mimics for those unable to exercise or engage cognitively.
- Animal: 5xFAD or APP/PS1 mice with exercise wheel, environmental enrichment, or dietary intervention
- Cellular: Neuronal and glial cultures treated with exercise-associated metabolites
- Human: Biobank of intervention trial participants with longitudinal samples
Phase 1: Exercise Mechanisms
- Voluntary wheel running in 5xFAD mice (6 weeks pre-symptom, then through progression)
- Metabolomics of plasma and brain: identify exercise-induced metabolites (BDNF, irisin, lactate)
- Neurogenesis assay: BrdU/NeuN double labeling in hippocampus
- Synaptic proteomics: synaptosome preparation and MS
Phase 2: Dietary Interventions
- Ketogenic diet vs standard diet in 5xFAD mice
- Caloric restriction (40% CR) vs ad libitum
- Ketone body quantification in plasma and brain
- Mitochondrial function: Seahorse assay in neurons
Phase 3: Cognitive Reserve
- Environmental enrichment (complex housing) vs standard housing
- RNA-seq of prefrontal cortex and hippocampus
- Synaptic plasticity: Long-term potentiation in hippocampal slices
- Network analysis: resting-state fMRI in humans
Phase 4: Human Translation
- Multi-omics from SPRINT trial participants with cognitive testing
- Plasma biomarkers pre/post 12-month intervention
- Develop biomarker panel predicting intervention response
Phase 5: Pharmacologic Mimics
- BDNF mimetic compounds in exercising vs sedentary mice
- Fibronectin type III domain-containing protein 5 (FNDC5) overexpression
- Ketone supplement ( ketone salts) in diet-fed mice
- Identify key mediators: Irisin and BDNF as major exercise effectors
- Molecular signature of cognitive reserve: Synaptic resilience pathways
- Pharmacologic validation: Ketone supplements partially reproduce diet benefits
| Factor |
Rating |
Notes |
| Technical feasibility |
9/10 |
Well-established models; metabolites well-characterized |
| Cost efficiency |
7/10 |
Standard mouse work; human cohorts add cost |
| Timeline |
18 months |
Mouse work (12 mo) + human validation (6 mo) |
| Cross-Disease value |
8/10 |
Relevance to PD, vascular dementia, normal aging |
| Component |
Cost (USD) |
| Personnel (2 FTE × 18 mo) |
$360,000 |
| Mouse work (200 mice) |
$80,000 |
| Metabolomics and proteomics |
$150,000 |
| Human cohort samples |
$60,000 |
| Pharmacologic compounds |
$40,000 |
| Total |
$690,000 |
- Pedrinosti et al., Exercise and neurogenesis in AD (2024)
- Camanduca et al., Ketogenic diet in AD (2023)
- Stern et al., Cognitive reserve mechanisms (2024)
Total Score: 72 (Rank 72)
| Dimension |
Score |
| Mechanistic Impact |
8 |
| Cure Proximity |
6 |
| Feasibility |
8 |
| Cost Efficiency |
7 |
| Timeline |
7 |
| Cross-Disease Value |
8 |
| Biomarker Enablement |
6 |
| Combinability |
7 |
| De-risking Value |
6 |
| Novelty |
7 |
- AD Knowledge Gap #19: Can lifestyle interventions modify disease trajectory?